Can someone remind Erb what he said at the last CC . We are also...

Can someone remind Erb what he said at the last CC .

We are also actively investigating several opportunities that will
complement our counterpulsation therapy and increase our
opportunities to develop a meaningful franchise in heart failure.
Before I turn the call over to Claudia, let me say a few words
about some upcoming clinical data and our current financial
situation. First, I am pleased to announce that data from our
OPTIONS-HF post-market study will be presented later this
month at the European Society of Cardiology Heart Failure
conference in Florence, Italy. While we can’t discuss the results
yet, we do expect the data to show improvements in cardiac
remodeling, functional capacity, and quality of life. We will issue a
press release with the results when the data is presented on May
21st. Finally, on the financial front, I am pleased with the progress
we have made in reducing our cash burn rate. Operating
expenses are down 35% from Q1 last year, and more importantly,
we have put in place a 2016 budget that not only reduces our
overall cash burn, but it does so while driving increased
productivity throughout the organization.
In terms of the balance sheet, we continue to expect to raise
additional capital in 2016. In that regard, we are actively exploring
our financing options. Ahead of that, we remain focused on
optimizing our clinical and product strategy in a way that creates a
business plan and financial opportunity that is both compelling
and achievable. We will continue to update you on meaningful
progress and will continue to establish near term milestones that
you can use to track our progress. I believe this will help us rebuild
credibility with investors which in turn, will help us identify
better financing options.
At this point, I’ll turn the call over to Claudia who can walk you
through our Q1 financial results. Following that, I’ll provide some
closing comments before taking your questions.
6​

Claudia